期刊文献+

骨髓增殖性肿瘤中JAK2V617F突变与Ⅰ型细胞因子受体相关性研究 被引量:12

Correlation between JAK2V617F Mutation and the Expression of Type Ⅰ Cytokine Receptors in Myeloproliferative Neoplasms
在线阅读 下载PDF
导出
摘要 目的探讨促红细胞生成素受体(EPOR)、粒细胞集落刺激因子受体(G-CSFR)、血小板生成素受体(MPL)在骨髓增殖性肿瘤(MPN)中的表达情况及其与JAK2V617F突变的相关性。方法选取44例BCR/ABL阴性MPN患者[包括16例真性红细胞增多症(PV)、14例原发性血小板增多症(ET)、14例原发性骨髓纤维化(IMF)患者]、11例慢性粒细胞白血病(CML)患者和20例健康志愿者(正常对照组)。应用定量逆转录聚合酶链反应(FQ-RT-PCR)技术检测上述受检者的骨髓或外周血JAK2V617F突变及EPOR、G-CSFR、MPL的mRNA表达情况。结果在44例BCR/ABL阴性的MPN患者中有26例(59.1%)存在JAK2V617F点突变,而在11例CML患者和20例正常对照者中未检测到JAK2V617F突变。BCR/ABL阴性MPN初治患者EPOR、G-CSFR的mRNA表达水平高于正常对照组(P<0.05),而MPL的mRNA表达水平与正常对照组比较差异无统计学意义(P>0.05);CML患者EPOR、G-CSFR、MPL的mRNA表达水平均高于正常对照组(P<0.05),BCR/ABL阴性JAK2V617F突变阳性与阴性初治组患者EPOR、G-CSFR、MPL的mRNA表达无明显差异(P>0.05)。结论Ⅰ型细胞因子和(或)JAK2V617F参与了MPN的发病;Ⅰ型细胞因子受体在多种造血系统肿瘤疾病中高表达,但对MPN的发病并非决定因素。 Objective To investigate the expressions of erythropoietin receptor (EPOR), granulocyte colony -stimu- lating factor receptor (G- CSFR) and thrombopoietin receptor (MPL) in chronic myeloproliferative neoplasms (MPN) and to discuss their correlations with JAK2V617F mutation. Methods The mRNA expressions of EPOR, GCSFR, MPL and JAK2V617F mutation in marrow or peripheral blood mononuclear cells in 44 patients with BCR/ABL negative chronic myeloprolif- erative neoplasms ( 16 for PV, 14 for ET, 14 for IMF) , 11 patients with CML and 20 healthy volunteers were measured with real - time fluorescent relative - quantification PCR ( FQ - PCR) . The correlation between cytokine receptors and JAK2V617F muta- tion in MPN patients were evaluated. Results 26 in 44 patients with BCR/ABL negative MPN had JAK2V617F mutation (59. 1% ) , while no JAK2V617F mutation was detected in 11 patients with CML and 20 normal controls, mRNA expression levels of EPOR and G - CSFR were significantly higher in patients with BCR/ABL negative MPN than those of normal controls ( P 〈 0. 05), but mRNA expression level of MPL in patients with BCR./ABL negative MPN showed no statistically significant differ- ences compared with normal controls ( P 〉 0. 05 ) . EPOR, G - CSFR and MPL mRNA expression levels were all significantly higher in patients with BCR/ABL positive CML ( P 〈 0. 05 ) . EPOR, G - CSFR and MPL mRNA expression levels were no sta- tisticly significant in JAK2V617F mutation or not BCR/ABL negative and untreated patients (P 〉 0. 05 ) . Conclusion Type I cytokine receptors and or JAK2V617F are involved in MPN pathogenesis, and type I eytokine receptor have high level expression in many hemopoietie system neoplasms, but it is not the major determinant.
出处 《中国全科医学》 CAS CSCD 北大核心 2012年第9期1019-1022,共4页 Chinese General Practice
关键词 骨髓增殖异常-骨髓增殖性疾病 受体 细胞因子 JAK2V617F 突变 Myelodysplastic - myetoproliferative diseases Receptor, cytokine JAK2V617F Mutation
  • 相关文献

参考文献2

  • 1Moliterno AR,Williams DM,Rogers O. Molecular mimicry in the chronic myeloproliferative disorders:reciprocity between quantitative JAK2V617F and Mpl expression[J].Blood,2006,(12):3913-3915.
  • 2Lacout C,Pisani DF,Tulliez M. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis[J].Blood,2006,(05):1652-1660.doi:10.1182/blood-2006-02-002030.

同被引文献110

  • 1邹煦,常炳庆,黄新春,龚浠平.骨髓增殖性疾病患者并发血栓性疾病的分析[J].中国卒中杂志,2012,7(10):775-780. 被引量:6
  • 2Zhang ZR, Duan YC. Interferon apha 2b for treating patients with JAK2V617F positive polycythemia vera and essential thrombocytosis[ J ] . Asian Pac J Cancer Prey, 2014, 15 (4) : 1681-1684.
  • 3Etheridge SL, Roh ME, Cosgrove ME, et al. JAK2V617F- positive endothelial cells contribute to clotting abnormalities in myeloproliferative neoplasms [ J ]. Proc Natl Acad Sci U S A, 2014, 111 (6) :2295-2300.
  • 4AbdE1Aal AA, Afify RA, Zaher AE, et al. Study of prognostic significance of marrow angiogenesis assessment in patients with de novo acute leukemia[ J]. Hematology, 2015, 20(9) :504-510.
  • 5Mosehetta MG, Maschio LB, Jardim-Perassi BV, et aL Prognostic value of vascular endothelial growth factor and hypoxia-indueible factor 1 c in canine malignant mammary tumors [ J ]. Oncol Rep, 2015, 33(5) :2345-2353.
  • 6Aguayo A. VEGF in chronic myeloid leukemia treated with interferon and imatinib [ J ]. Leuk Res, 2014, 38 ( 6 ) :660-661.
  • 7Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management [ J ]. Am J Hematol, 2015, 90 ( 2 ) : 162-173.
  • 8Walz C, Crowley B J, Hudon HE, et al. Activated Jak2 with the V617F point mutation promotes G1/S phase transition [ J ]. J Biol Chem, 2006, 281 (26) :18177-18183.
  • 9Medinger M, Skoda R, Gratwohl A, et al. Angiogenesis and vascular endothelial growth factor-/receptor expression in myeloproliferative neoplasms: correlation with clinical parameters and JAK2-V617F mutational status [ J 1. Br J Haematol, 2009, 146(2) :150-157.
  • 10Boiocchi L, Vener C, Savi F, et al. Increased expression of vascular endothelial growth factor receptor 1 correlates with VEGF and microvessel density in Philadelphia chromosome-negative myeloproliferative neoplasms[ J ]. J Clin Pathol, 2011, 64 ( 3 ) : 226 -231.

引证文献12

二级引证文献54

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部